In contrast, HER2-targeted therapy in HER2-amplified PDA has only limited activity, which may be due, at least in part, to a higher frequency of KRAS mutations in this disease [28,29,30]. The gene discussed is ERBB2; the disease is Patent ductus arteriosus.